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In our Supplemental Newborn Screening Program in western Pennsylvania, we
have introduced not only a unique approach to newborn screening, but also some
innovative conceptsinfollow-upconfirmation andprognostic diagnosis. The Pennsyl-
vania Department ofHealth routinely screens onlyfor phenylketonuria and congen-
ital hypothyroidism. In an attempt to extend this basic state-mandated screening
program, we developed, in 1986, the concept of an independent supplemental
fee-for-service screening program. At present we are screening 37 hospitals plus a
number ofnurse midwifery programs inwestern Pennsylvania and eastern Ohio. We
routinely screen for 11 inherited metabolic disorders: sickle-cell disease, congenital
adrenal hyperplasia, galactosemia, biotinidase deficiency, maple syrup urine disease,
homocystinuria, cystic fibrosis, Duchenne muscular dystrophy, glucose-6-phosphate
dehydrogenase deficiency, pyroglutamic aciduria, and arginase deficiency. Having
the opportunity to design our program from the start has permitted us to include
screening for conditions with extensive worldwide experience and acceptance, as
well as for lesser-known and lesswidely accepted conditions. It has also allowed us to
develop and introduce some exciting new technologies as part of our routine
confirmation procedures.
Newborn screening for cystic fibrosis (CF), using immunoreactive trypsinogen
(IRT), was first introduced in New Zealand over ten years ago [1]. Today, well over
3.2 million newborns have been screened worldwide, using this procedure [2]. In the
United States, screening isonlybeing done in Colorado, Wisconsin, at 13 hospitals in
Conneticut, and by our program. Amajorjustification for newborn screening for CF
has been that at least half of the patients with CF go undiagnosed during the first
year oflife, while 25 percent remain undiagnosed by the end oftheir second year. In
addition, a number of clinical benefits have been shown to be associated with early
diagnosis and early treatment [3-5].
One limitation of newborn CF screening using IRT is the age-dependence of the
elevation. Bythree to sixmonths ofage, the pancreashasbegun toburn out orhas, in
fact, already burned out, with the result that reliable screening and retesting is
limited to the early weeks or months of life; that circumstance requires a declining
cut-off with increasing age. This complexity potentially increases the risk of false-
negatives. A second problem with newborn IRT screening is a higher than comfort-
able false-positive rate. Depending on the program, between two and ten patients
are referred for sweat testing in order to confirm one case ofCF. While this number
is not an extremely high false-positive rate as screening tests go, it is higher than we
would like because ofthe severe degree ofanxiety created for the family. Therefore,
if there is anything that we can do to decrease this false-positive rate, while at the
same time increasing our detection rate, we have attempted to do it.
In the case of newborn CF screening, our approach has been to use molecular
genetic techniques to back up our initial IRT results. Using polymerase chain
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FIG. 1. Diagnosis of cystic fibrosis: amplification product of DNA, using the AF508 mutation as a
primer from neonatal specimens (lanes 2-8). The reaction product of the negative control (no DNA) is
seen in lane 9. The amplified product of an individual heterozygous for the deletion is in lane 4; one
homozygous for the deletion is in lane 7. Lanes 1 and 10 contain the DNA size markers 4OX174 Hae III
restriction fragments.
reaction (PCR) amplification of the DNA eluted from a single filter paper blood
spot, we are able to screen for the presence of the common three base pair deletion
(delta F508) associated with CF [6]. Among known patients with CF, 50 percent are
homozygous for this deletion, while another 41-44 percent are mixed heterozygotes
for the delta F508 deletion plus a second mutant allele. The remaining 6-9 percent
have two copies ofmutations other than the delta F508 deletion. This information is
illustrated in Fig. 1.
Since January 1990, we have been performing PCR amplification for the delta
F508 deletion on everyfilter paperbloodspecimen inwhich wefind an elevated IRT.
We expect that thispracticewill improve both the sensitivity and specificity ofour CF
screening program in two ways. The ability to combine IRT elevations with delta
F508 status should reduce the risk of a potential false-negative resulting from an
inaccurate sweat test. We also hope to be able to redefine our IRT screening cut-off
level and follow-up criteria, using a combination ofIRT and delta F508 status, in the
hope ofreducing the number offalse-positives that are referred for sweat testing.
A second area where we have introduced new molecular genetic technologies as
part of our routine confirmationprocedures is in our newborn screening program for
Duchenne muscular dystrophy (DMD). The worldwide screening experience, which
uses elevated creatine kinase as a marker, is not nearly as extensive as that for CF
and many other disorders. Nevertheless, over 800,000 newborns have been screened,
primarily in West Germany, France, Manitoba, Canada, and New Zealand [7-10].
Our program has screened approximately 73,000 newborns, including 20,000 speci-
mens from Sao Paulo, Brazil, through March 31, 1990. We have had 111 initial
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FIG. 2. Diagnosis of Duchenne muscular dystrophy (DMD): Multiplex amplification products of
DNA from eight neonatal specimens (lanes 4-11), using the DMD gene as primer. Lane 2 demonstrates
the nine normal bands generated by DNA from a normal individual. Lane 3 contains DNA from an
individual with a deletion ofeight of the nine exons in the DMD gene. Lanes 1 and 12 contain the DNA
size markers4OX174 Hae III restriction fragments.
elevations, 12 persistent elevations on repeat testing, and ten confirmed cases of
DMD, giving us an incidence of 1/7,300 newborns ofboth sexes.
Unlike the situation with CF, we are not primarily concerned about eliminating
false-positives or false-negatives with DMD screening. Rather, we are trying to
provide rapid confirmation ofthe diagnosis as early as possible, preferablybefore the
patient iseven referred to a DMD clinic forclinical evaluation andmuscle biopsy. To
do this, we are using multiplex PCR amplification of DNA from the initial filter
paper blood specimens ofnewbornswith two creatine kinase elevations [11,12]. Due
in part to very large size, the gene mutations responsible for DMD can be directly
identified in 65 percent of patients as deletions of specific exons within the dystro-
phin gene [13]. Using multiplex PCR, we are able to identify 80 percent of these
deletions and, therefore, confirm the diagnosis in approximately halfof our patients
before we even request a follow-up quantitative serum creatine kinase. We feel that
this confirmation helps significantly in the early management of the patient and
family. Figure 2illustrates an example ofamultiplexPCRamplification ofa newborn
DMD patientwith a significant deletion.
As part of an expanded confirmation protocol, we routinely request quantitative
serum creatine kinase analysis, clinical evaluation, family history, and routine
histology of a muscle biopsy for confirmation of the diagnosis. We also carry out
additional Southern blot analysis on the patient, using various probes to define
further and characterize the mutation or deletion at the DNA level. This practice,
together with the multiplex PCR studies, can provide the basis for carrier testing of
at-risk family members andpotentially has some prognosticvalue. Also, in collabora-
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tion with Dr. Eric Hoffman, we are determining the dystrophin status ofthe muscle,
using both immunoblot and immunofluorescent assays on biopsies [14-15]. This
technique permits us to distinguish the more severe DMD from the milder Becker
muscular dystrophy in an asymptomatic newborn with no positive family history.
Without this expanded follow-up protocol, one might have to wait for years to
determine the patient's prognosis.
In summary, what we have done is to adapt several molecular genetic techniques
for use with DNA eluted from filter paper blood specimens and to incorporate these
into the routine follow-up and confirmation protocols forour supplemental newborn
screening program for DMD and CF. While we are notusingmultiplex PCR or delta
F508 analysis for primary screening or carrier testing, we are using these techniques
to improve the sensitivity and specificity of our existing creatine kinase and IRT
screening for DMD and CF, respectively. As automated procedures are developed
and as the cost decreases, however, we are optimistic that the use ofthese or similar
molecular tests on filter paper blood specimens will become practical for primary
screening in the not too distant future.
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